A retrospective, observational multicenter study evaluating the efficacy and safety profile of durvalumab use after chemoradiation (CRT) in patients with stage III non small cell lung cancer
Latest Information Update: 04 Dec 2020
At a glance
- Drugs Durvalumab (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 04 Dec 2020 New trial record
- 23 Nov 2020 Results published in the European Journal of Cancer